Cellyan Biotechnology reported total assets of $12.84M and total liabilities of $3.26M for the quarter ended Mar 2026, up 48.2% year over year. This balance sheet covers 5 quarters of results from Mar 2024 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Mar2024 | Sep2024 | Mar2025 | Sep2025 | Mar2026 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & EquivalentsCash & Equiv. | 0.63M | 0.63M | 0.75M | 0.19M | 0.22M |
| Cash & Current Investments | 0.63M | 0.63M | 0.75M | 0.19M | 0.22M |
| Receivables - NetNet Receivables | 3.70M | 4.88M | 4.66M | 5.09M | 3.78M |
| Receivables - OtherOther Receivables | 0.02M | 0.01M | 0.06M | 0.01M | 0.01M |
| Receivables | 3.72M | 4.90M | 4.71M | 5.11M | 3.79M |
| Inventory | 0.93M | 0.56M | 0.56M | 0.59M | 0.36M |
| Prepaid Assets | 1.26M | 0.90M | 0.45M | 0.68M | 7.96M |
| Current Assets | 7.80M | 8.88M | 8.73M | 8.86M | 12.33M |
| Non-Current Assets | |||||
| Property, Plant & Equipment (Net)PP&E (Net) | 0.87M | 1.28M | 0.69M | 0.78M | 0.51M |
| Long-Term Investments | -2.30M | ||||
| Intangibles | 0.03M | 0.13M | 0.13M | 0.13M | |
| Goodwill & Intangibles | 0.03M | 0.09M | 0.10M | 0.09M | 0.08M |
| Long-Term Deferred Tax | 1.26M | ||||
| Other Non-Current Assets | 0.01M | 401.00 | 400.00 | 459.00 | |
| Non-Current Assets | 0.87M | 1.28M | 0.69M | 0.78M | 0.51M |
| Assets | 8.67M | 10.16M | 9.42M | 9.63M | 12.84M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payables | 1.42M | 1.80M | 1.82M | 1.23M | 0.87M |
| Notes Payables | 0.50M | 0.24M | 0.00M | 0.34M | 0.98M |
| Payables | 1.92M | 2.04M | 1.82M | 1.57M | 1.86M |
| Short term Debt | 0.18M | 0.23M | 0.37M | 0.36M | 0.88M |
| Current Leases | 0.63M | 0.91M | 0.49M | 0.45M | 0.31M |
| Current Taxes | 0.22M | 0.35M | 0.11M | 0.12M | 0.02M |
| Current Deferred Revenue | 0.19M | 0.07M | 0.12M | 0.53M | 0.13M |
| Total Current Liabilities | 3.18M | 3.60M | 2.92M | 3.03M | 3.20M |
| Non-Current Liabilities | |||||
| Non-Current Debt | 1.12M | 1.01M | 1.50M | 1.33M | |
| Operating Leases | 0.12M | 0.20M | 0.01M | 0.13M | 0.07M |
| Total Non-Current Liabilities | 1.24M | 1.21M | 1.51M | 1.46M | 0.07M |
| Total Liabilities | 4.41M | 4.81M | 4.43M | 4.49M | 3.26M |
| Shareholder's Equity | |||||
| Total Debt | 1.80M | 1.48M | 1.88M | 2.03M | 1.86M |
| Common Equity | 4.99M | 5.14M | 9.58M | ||
| Liabilities and Shareholders Equity | 8.67M | 10.16M | 9.42M | 9.63M | 12.84M |
| Retained Earnings | 3.02M | 3.02M | 3.46M | 3.46M | 8.95M |
Pull Cellyan Biotechnology's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=HKPD&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "HKPD", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=HKPD&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();